Liquid Biopsy in Neuropsychiatric Disorders: A Step Closer to Precision Medicine

Overview

Journal Mol Neurobiol

Specialties Molecular Biology
Neurology

Date 2024 Sep 19

PMID 39298102

Authors

Perla El-Ahmad

Ana Paula Mendes-Silva

Breno S Diniz

Affiliations

Soon will be listed here.

Abstract

Psychiatric disorders are among the leading causes of disease burden worldwide. Despite their significant impact, their diagnosis remains challenging due to symptom heterogeneity, psychiatric comorbidity, and the lack of objective diagnostic tests and well-defined biomarkers. Leveraging genomic, epigenomic, and fragmentomic technologies, circulating cell-free DNA (ccfDNA)-based liquid biopsies have emerged as a potential non-invasive diagnosis and disease-monitoring tool. ccfDNA is a DNA species released into circulation from all types of cells through passive and active mechanisms and can serve as a biomarker for various diseases, namely, cancer. Despite their potential, the application of ccfDNA in neuropsychiatry remains underdeveloped. In this review, we provide an overview of liquid biopsies and their components, with a particular focus on ccfDNA. With a summary of pre-analytical practices and current ccfDNA technologies, we highlight the current state of research regarding the use of ccfDNA as a biomarker for neuropsychiatric disorders. Finally, we discuss future steps to unlock ccfDNA's potential in clinical practice.

References

Rehm J, Shield K . Global Burden of Disease and the Impact of Mental and Addictive Disorders. Curr Psychiatry Rep. 2019; 21(2):10. DOI: 10.1007/s11920-019-0997-0. View

Bardelli A, Pantel K . Liquid Biopsies, What We Do Not Know (Yet). Cancer Cell. 2017; 31(2):172-179. DOI: 10.1016/j.ccell.2017.01.002. View

Marrugo-Ramirez J, Mir M, Samitier J . Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy. Int J Mol Sci. 2018; 19(10). PMC: 6213360. DOI: 10.3390/ijms19102877. View

Alix-Panabieres C, Schwarzenbach H, Pantel K . Circulating tumor cells and circulating tumor DNA. Annu Rev Med. 2011; 63:199-215. DOI: 10.1146/annurev-med-062310-094219. View

Joosse S, Pantel K . Tumor-Educated Platelets as Liquid Biopsy in Cancer Patients. Cancer Cell. 2015; 28(5):552-554. DOI: 10.1016/j.ccell.2015.10.007. View

Chen L, Bode A, Dong Z . Circulating Tumor Cells: Moving Biological Insights into Detection. Theranostics. 2017; 7(10):2606-2619. PMC: 5558556. DOI: 10.7150/thno.18588. View

Visal T, den Hollander P, Cristofanilli M, Mani S . Circulating tumour cells in the -omics era: how far are we from achieving the 'singularity'?. Br J Cancer. 2022; 127(2):173-184. PMC: 9296521. DOI: 10.1038/s41416-022-01768-9. View

Roweth H, Battinelli E . Lessons to learn from tumor-educated platelets. Blood. 2021; 137(23):3174-3180. PMC: 8351883. DOI: 10.1182/blood.2019003976. View

Best M, Sol N, Kooi I, Tannous J, Westerman B, Rustenburg F . RNA-Seq of Tumor-Educated Platelets Enables Blood-Based Pan-Cancer, Multiclass, and Molecular Pathway Cancer Diagnostics. Cancer Cell. 2015; 28(5):666-676. PMC: 4644263. DOI: 10.1016/j.ccell.2015.09.018. View

10.

Liu C, Zhao J, Tian F, Cai L, Zhang W, Feng Q . Low-cost thermophoretic profiling of extracellular-vesicle surface proteins for the early detection and classification of cancers. Nat Biomed Eng. 2019; 3(3):183-193. DOI: 10.1038/s41551-018-0343-6. View

11.

Doyle L, Wang M . Overview of Extracellular Vesicles, Their Origin, Composition, Purpose, and Methods for Exosome Isolation and Analysis. Cells. 2019; 8(7). PMC: 6678302. DOI: 10.3390/cells8070727. View

12.

Liang Y, Lehrich B, Zheng S, Lu M . Emerging methods in biomarker identification for extracellular vesicle-based liquid biopsy. J Extracell Vesicles. 2021; 10(7):e12090. PMC: 8114032. DOI: 10.1002/jev2.12090. View

13.

Grabuschnig S, Bronkhorst A, Holdenrieder S, Rosales Rodriguez I, Schliep K, Schwendenwein D . Putative Origins of Cell-Free DNA in Humans: A Review of Active and Passive Nucleic Acid Release Mechanisms. Int J Mol Sci. 2020; 21(21). PMC: 7662960. DOI: 10.3390/ijms21218062. View

14.

Szilagyi M, Pos O, Marton E, Buglyo G, Soltesz B, Keseru J . Circulating Cell-Free Nucleic Acids: Main Characteristics and Clinical Application. Int J Mol Sci. 2020; 21(18). PMC: 7555669. DOI: 10.3390/ijms21186827. View

15.

Mandel P, Metais P . Nuclear Acids In Human Blood Plasma. C R Seances Soc Biol Fil. 1948; 142(3-4):241-3. View

16.

Tan E, Schur P, Carr R, KUNKEL H . Deoxybonucleic acid (DNA) and antibodies to DNA in the serum of patients with systemic lupus erythematosus. J Clin Invest. 1966; 45(11):1732-40. PMC: 292857. DOI: 10.1172/JCI105479. View

17.

Leon S, Shapiro B, SKLAROFF D, Yaros M . Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res. 1977; 37(3):646-50. View

18.

Stroun M, Anker P, Maurice P, Lyautey J, LEDERREY C, Beljanski M . Neoplastic characteristics of the DNA found in the plasma of cancer patients. Oncology. 1989; 46(5):318-22. DOI: 10.1159/000226740. View

19.

Vasioukhin V, Anker P, Maurice P, Lyautey J, LEDERREY C, Stroun M . Point mutations of the N-ras gene in the blood plasma DNA of patients with myelodysplastic syndrome or acute myelogenous leukaemia. Br J Haematol. 1994; 86(4):774-9. DOI: 10.1111/j.1365-2141.1994.tb04828.x. View

20.

Bryzgunova O, Konoshenko M, Laktionov P . Concentration of cell-free DNA in different tumor types. Expert Rev Mol Diagn. 2020; 21(1):63-75. DOI: 10.1080/14737159.2020.1860021. View